July 14, 2017 / 1:05 PM / 2 months ago

BUZZ-FDA panel okays Mylan, Biocon's copy of Roche's Herceptin

(Updates)

** Generic drugmaker’s shares up about 2 pct at $39.80 in light premarket trading

** Advisory committee to FDA unanimously recommends approval for its biosimilar

** Oncologic Drugs Advisory Committee votes 16-0 in support of MYL’s and Biocon Ltd’s biosimilar version of Roche Holding AG’s breast cancer treatment Herceptin

** FDA not obliged to follow recommendations of its advisers but typically does so

** Mylan and Biocon are exclusive partners on a broad portfolio of biosimilar and insulin products

** BION rose as much as 10 pct to 404.45 rupees

** Up to Thursday’s close, MYL had risen 2.4 pct this year, while Biocon gained 16 pct

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below